The AADACL2 (arylacetamide deacetylase-like 2) antibody is a tool used to study the AADACL2 protein, a member of the arylacetamide deacetylase (AADAC) enzyme family. AADAC enzymes are primarily involved in hydrolyzing exogenous substrates, including drugs, toxins, and lipid metabolites. AADACL2 shares structural homology with AADAC, particularly in its catalytic domain, but its precise physiological role remains less characterized compared to the well-studied AADAC.
AADACL2 is thought to function as a carboxylesterase, potentially influencing drug metabolism, lipid homeostasis, or detoxification pathways. It is expressed in tissues such as the liver, gastrointestinal tract, and adipose tissue, suggesting roles in systemic metabolic regulation. Research has linked AADACL2 to conditions like obesity, metabolic syndrome, and cancer, though mechanistic insights are still emerging. For example, altered AADACL2 expression has been observed in hepatocellular carcinoma and colorectal cancer, hinting at its involvement in tumor progression or drug resistance.
The AADACL2 antibody enables detection and quantification of the protein in experimental models (e.g., Western blot, immunohistochemistry). It is critical for exploring its interaction with therapeutic agents, metabolic pathways, or disease biomarkers. Current studies focus on clarifying its substrate specificity, regulatory mechanisms, and potential as a therapeutic target. However, challenges persist in distinguishing its activity from related enzymes, necessitating rigorous validation of antibody specificity in research applications.